Non-celiac Gluten Sensitivity (NCGS)
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Non-celiac Gluten Sensitivity (NCGS)
Non-celiac gluten sensitivity (NCGS) refers to a condition where gluten intake results in intestinal or extra-intestinal symptoms that resolve upon removal of gluten from the diet. As a leading research service provider, Protheragen has specialized services for NCGS and other rare gastrointestinal disorders to expedite the work on effective therapy for individuals suffering from these ailments.
Non-celiac gluten sensitivity (NCGS) is characterized by the onset of digestive and other symptoms several hours or a few days after eating something that has gluten. It is not due to celiac disease (CD) or wheat allergy (WA). Individuals suffering from NCGS most commonly report gastrointestinal problems such as abdominal pain, bloating, and altered bowel movements.
Fig.1 Predisposing factors of NCGS. (Cárdenas-Torres, F. I., et al., 2021)
The mechanisms that account for the pathogenesis of NCGS are not well elucidated but they are expected to be highly sophisticated and to contain many components, with a major role assumed to the innate immune system. In broad outlines, the conception is that gliadin can bring about an increase of intestinal permeability in a temporary fashion, heightened intestinal permeability promotes the entry of gliadin and other large molecular antigens into the lamina propria, in which the host elicits primary attempts at defense such as neutrophil recruitment at the site of exposure.
Comparative analysis of intestinal biopsies from NCGS individuals' healthy persons and CD individuals shows those suffering from NCGS have higher TLR2 levels and lower levels of regulatory T cell marker FOXP3.
Fig.2 Current evidence for the pathogenic mechanisms of NCGS. (Cárdenas-Torres, F. I., et al., 2021)| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| Probiotic ES1 | Colonizing in the human gastrointestinal tract and having a lytic activity on gliadin. | / | NCT02810301 | Phase II |
| BL NCC 2705 | Modulation of immunopathology caused by gliadin. | / | NCT03775499 | N/A |
| AN-PEP | Lower gluten content in the small intestine by its degradation in the stomach. | Peptide | NCT02060864 | N/A |
| Endopeptidase P1016 | With high specificity toward the breakdown of proline-rich gluten epitopes. | Peptide | NCT01864993 | N/A |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
With the use of the latest technology and analytics, we track and interpret data in a way that brings considerable value to decision-making. Our offerings in these areas are designed to assist in developing possible therapies for such an intricate condition including services focused on diagnostics, therapeutics, and disease modeling. Moreover, we also offer pharmacokinetics and drug safety evaluation services to meet the specific needs of NCGS.
Models with animals are critical in expanding knowledge on NCGS as well as therapy development. We develop animal models for researchers and pharmaceutical companies focusing on NCGS and related conditions tailored to their requirements.
The utilized animal was subjected to gluten or gliadin to trigger the primary immune system response and some inflammation within the intestines that are characteristic of NCGS.
At Protheragen, we recognize the complexities encountered while studying uncommon gastrointestinal disorders like NCGS. This drives us to partner with pharmaceutical and biotechnology firms to streamline the development of effective therapies for researchers studying NCGS and related disorders. If you would like to learn more about our services, please contact us right away!
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.